Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Arnob Banerjee et al.|Blood Advances|2023Cited by 85
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 StudyDonna Catamero, Sandy Kruyswijk, Patricia Blázquez Benito et al.|Seminars in Oncology Nursing|2024Cited by 3
NSP-04 Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 studyDonna Catamero, Sandy Kruyswijk, Patricia Blázquez Benito et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0